All Type of News
Starting age for cervical cancer checkup is extended to 20 or above
In the future, the screening cycle for liver cancer will be shortened from a year to 6 months, and the checkup target for cervical cancer will be extended from the age of 30 to 20 or above.
The Ministry of Health and...
Drug Research Association proposes ‘Expansion Of Target Technology For Tax Deduction On Pharmaceutical R&D Expenses’
The Korea Drug Research Association(Chairperson Dong-yeon Kim) submitted the ‘Opinions For The Review Of Technology Targeting Tax Deduction On New Growth Engine and Source Technology Research and Development’(Recommen...
MFDS starts to make ‘Korean Orange Book’ containing generic approval information
The government attracted attention as deciding to make the ‘Korean Orange Book’ containing details about domestic approvals for generic products.
From this March, bioequivalent test results and details are obligated ...
Genzyme reborn as Sanofi-Genzyme Korea
A pharmaceutical company specializing in rare diseases, Genzyme has been re-born as a Sanofi Group’s ‘Sanofi Genzyme’ department.
According to the industry concerned on the 19th, the Sanofi’s Korean branch confirmed ...
Gardasil and Servarix on a log bridge
As expected, both ‘Gardasil’ and ‘Servarix’ were selected as vaccines for the National Immunization Program for cervical cancer, but the real competition has not been started. This is because how to calculate prices o...
The impact of Hanmi Flu on Tamiflu
Tamiflu, which has been the only treatment for influenza A & B, seems to be significantly influenced by Hanmi Flu that will be launched on the 26th.
The pharmaceutical distribution expects Tamiflu, which has enjoyed ...
Celltrion acquires substance patent of Herceptin biobetterCelltrion acquired a patent of the Antibody-Drug Conjugate(ADC) substance, a new drug treating breast cancer, from the Korean Intellectual Property Office on the 18th.
The pate...
|
Late entry of 10 year old constipation drug into domestic market
A Takeda Pharmaceutical’s chronic idiopathic constipation therapy is expected to land in Korea after the 10th anniversary for its global approval.
On the 18th, the Ministry of Food and Drug Safety(MFDS) announced ‘Lu...
“How come indications that are foreignly approved cannot be used in Korea?”
Patients have suffered from an incident where an indication was approved by the U.S. FDA, not in Korea. In other words, the rights to access new drugs have been restricted.
If myelodysplastic syndrome is not treated,...
Hanmi wins Viagra’s design trialsA Hanmi Pharm’s erectile dysfunction treatment, Palpal was finally confirmed not to infringe the Viagra’s trademark right.
On the 18th, the 4th Civil Division, Seoul High Court...
|
